BMS wins expanded OK for Baraclude; U.K. nixes generic substitution;

 @FiercePharma: New migraine use for Botox could be worth $1B. Article | Follow @FiercePharma

Special Report: Pharma's Biggest Flops. Report

> Bristol-Myers Squibb said FDA approved its hepatitis B treatment Baraclude for patients with a more severe form of liver disease. Report

> The coalition government has abandoned a new provision in the proposed Pharmaceutical Price Regulation Scheme that could have allowed pharmacists to swap a doctor-prescribed branded medicine with a generic substitute in an effort of cost-effectiveness. Story

> Taking statin drugs may lower the risk of colon cancer by 12 percent, according to a meta-analysis covering over 2.5 million people. Article

> A week of global anti-counterfeiting law enforcement coordinated by Interpol led to the shutdown of 290 websites, seizure of 11,000 packages and confiscation of 1 million pills. Report

> Natco Pharma has said that Revlimid-maker Celgene has filed a lawsuit against the Indian company's application for FDA approval for a generic version of the drug. Item

>Pfizer closed to the media a Tuesday political candidates forum that the company is jointly sponsoring with the Connecticut Business and Industry Association. Report

> Shares in Novo Nordisk extended earlier losses amid concerns the world's largest insulin maker could face rising competition from cheap new diabetes drugs. News

Biotech News

 @FierceBiotech: Sanofi will attend Harvard in hunt for new blockbusters. Article| Follow @FierceBiotech

 @JohnCFierce:Peregrine brain cancer drug more than triples survival rate--vs non-treatment--for 14 patients in mid-stage study. Article | Follow @JohnCFierce

> Study: That 'placebo effect' may have a hidden meaning. News 

> Why are women thriving in the top ranks of biotech? Article 

> Pearl lands $69M Series C for mid-stage COPD program. Report 

> Transcept readies second attempt at sleep drug approval. Story 

> Pfizer's new biosimilar insulin pact dents high-flying Novo. Article 

Biotech Research News

> GSK sees new value in treatments for rare diseases. Article 

> Urine test could predict prostate cancer. News 

> Wellcome Trust worries about immigration laws. Story 

> Ovarian cancer detection study disputed. Report 

> A PiggyBac ride to genetic causes of cancer. Article 

> New technique may increase healthy IVF births. News 

Manufacturing News

> Teva finds regulatory VP at FDA gate. Story

> FDA probes SPL over contaminated heparin. News

> GAO joins FDA in congressional spotlight. Report 

> Hackers hijack Microsoft's servers for fake-drug spam. Item

> Compliance packaging to benefit from healthcare reform. Story 

And Finally... Bayer's Factor Xa anticoagulant Xarelto scooped the Best Pharmaceutical Agent award at the prestigious Prix Galien ceremony. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.